{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T07:11:11Z","timestamp":1725606671609},"reference-count":29,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2007,8,24]],"date-time":"2007-08-24T00:00:00Z","timestamp":1187913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2007,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Administration of pegylated interferon\u2010alpha (IFN\u2010alpha) and ribavirin in adults with chronic hepatitis C (CHC) is a recommended therapeutic standard. Nevertheless, this therapeutic regimen rises numerous controversies. The aim of this study was to analyze adverse effects during the treatment with pegylated IFN\u2010alpha and ribavirin in children with CHC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Study group comprised 30 children with CHC, age 8\u201319 years (mean 13,6 years), 9 girls and 21 boys. All patients were administered two medication therapy with pegylated IFN\u2010alpha\u20102b in the dose of 1.5\u2009\u00b5g\/kg of body weight 1\u00d7\/week subcutaneously and daily oral ribavirin 15\u2009mg\/kg of bodyweight for 48 weeks. Blood samples were taken at baseline and every 4 weeks during the whole treatment and 24 weeks of follow\u2010up period. Panel of test included: cellular blood count and smear, ALT activity, bilirubin level. Patients complaints were noticed during every visit. Thyroid hormones and antibodies were checked every 3 months. Children were divided into group A that responded to treatment and group B\u2014nonresponders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Abnormalities in laboratory tests (white blood cells, neutrophils, haemoglobin) were observed mainly during first weeks of treatment. Mean bilirubin level and platelets were normal. Mean ALT normalized during the treatment. After 12\u201316\u2009weeks of the therapy somatic adverse effects decreased significantly.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Administration of pegylated IFN\u2010alpha and ribavirin in children with CHC is related to characteristic adverse effects. Periodical dose reduction was necessary. Although side effects and subjective patient complaints were present, children attended school without difficulties. Constant monitoring is required during the whole treatment. Copyright \u00a9 2007 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.1458","type":"journal-article","created":{"date-parts":[[2007,8,27]],"date-time":"2007-08-27T21:16:54Z","timestamp":1188249414000},"page":"1095-1103","source":"Crossref","is-referenced-by-count":11,"title":["Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C"],"prefix":"10.1002","volume":"16","author":[{"given":"Arleta","family":"Kowala\u2010Piaskowska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwona","family":"Mozer\u2010Lisewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Figlerowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"S\u0142u\u017cewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,8,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200107053450107"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20030"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20225"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200001273420414"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510280534"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-4-431-68255-4_40"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001432-199906000-00015"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-004-1418-9"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-199909000-00014"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(94)90058-2"},{"issue":"10","key":"e_1_2_1_12_2","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jama.1991.03470100067035","article-title":"The interferons. Mechanisms of action and clinical applications","volume":"266","author":"Baron S","year":"1991","journal-title":"JAMA"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(02)00027-3"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mpg.0000235974.67496.e6"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/82191"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.111085598"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1665-2681(19)32139-8"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20661"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e31802dd2f6"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0248-8663(02)00659-8"},{"issue":"2","key":"e_1_2_1_23_2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000150362","article-title":"Current state of interferon therapy for chronic hepatitis C","volume":"37","author":"Iino S","year":"1994","journal-title":"Intervirology"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(96)80113-9"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02208597"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260130"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20884"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.36495"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392101"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.30.2.201"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1458","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1458","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1458","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:39:41Z","timestamp":1700008781000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,24]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["10.1002\/pds.1458"],"URL":"https:\/\/doi.org\/10.1002\/pds.1458","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,24]]}}}